News and Trends 28 Mar 2017 Swiss Antibodies Recruited by the Developer of BMS’ Cancer Blockbuster Ono Pharmaceutical is offering the Swiss Numab €241M (CHF 258M) for the development of a multi-specific antibody for immuno-oncology applications. Numab, one of the hottest biotechs in Zurich, has developed a unique technology to generate stable antibody fragments (not an easy feat!) and use them as building blocks for multi-specific antibodies that can target up […] March 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2017 Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market? Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy” to biotech. On July 20, 2012, the western world’s first gene therapy, Glybera, received marketing authorization from the EMA. The treatment was designed and developed by uniQure as one-off treatment for Lipoprotein Lipase Deficiency (LPLD), a […] March 28, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2017 You Can Now Search Worldwide Genomic Data in a Single Platform Access to data is still the main bottleneck for genomic researchers. Repositive has created a free online platform to solve this problem once and for all. Repositive is building an online platform that makes genomic data from different sources easily searchable and accessible from a single portal. Its mission is to speed up genetic diagnostics […] March 27, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 27 Mar 2017 Meet one of the Most Successful Biotech Entrepreneurs in the UK Jonathan Milner is a rockstar biotech entrepreneur and founder of Abcam. He is still on the board of his baby Abcam, while investing in many young startups, nurturing the British biotech ecosystem and taking part in philanthropy. Here’s my chat with him on all these topics. “I was amazed by how you could order books […] March 27, 2017 - 7 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2017 Novartis puts the Development of two Anti-Aging Drugs in American Hands PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio of PureTech, a Boston-based healthcare company listed on the London stock market. Originally an investment firm, it now has put together a drug pipeline from […] March 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 24 Mar 2017 This Swedish Biotech Uses Bacteria to Treat Diseases in Infants This week’s biotech brought us to Scandinavia. Based in Sweden’s capital, Stockholm, Infant Bacterial Therapeutics aims to treat rare diseases affecting newborns by targeting the infant microbiome. Mission: Infant Bacterial Therapeutics (IBT) aims to treat rare diseases affecting infants for which there is currently no treatment available. The company makes use of live bacterial therapeutics, which modulate inflammatory […] March 24, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2017 New Biochips Quickly Identify the Best Antibiotic for each Bacterial Infection Scientists from Israel have piloted a new silicon biosensor chip that can rapidly identify the best antibiotics for treating a bacterial infection. Antibiotic resistance makes up one of the major health challenges of the 21st century. Some of the major causes of the increasing numbers of resistant bacterial strains are overuse of antibiotics and mistreatment of infections. […] March 24, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2017 A Cheaper Heat-Stable Vaccine Could Prevent Child Deaths in Africa An innovative rotavirus vaccine, BRV-PV, which does not require refrigeration, has passed Phase III trials in children living in sub-Saharan Africa. The Research and Epidemiology branch of the humanitarian organization Doctors without Borders (MSF), Epicentre, has published the results of its recent Phase III trial for a new oral vaccine against rotavirus infection. The vaccine, […] March 23, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2017 Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug Galapagos has announced to kick off a Phase I trial with its novel Cystic Fibrosis potentiator GLPG3067, triggering a €7M milestone payment from AbbVie. Galapagos and AbbVie teamed up in 2013, with the aim of developing a triple combination therapy for the treatment of Cystic Fibrosis (CF). Now, Galapagos announced the start of a Phase […] March 23, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 23 Mar 2017 Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics Located right here in Barcelona, Oryzon is one of the world’s few epigenetics biotechs. I sat down with CEO Carlos Buesa to talk about its approach. Since its foundation in 2000, Oryzon has gone on to become the leader in epigenetic medicine and focuses on oncology. Most recently, the company announced the success of its lead […] March 23, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2017 Speed up R&D? Eppendorf is Offering a new Solution! With their latest bioreactor system, BioFlo 120, Eppendorf is aiming to make bioprocesses more flexible and straightforward. Apart from brewing beer, bioprocesses play a major role in the biotech industry. Ever since the breakthrough of genetic engineering technologies in the end of the last century, we have started to exploit microorganisms or mammalian cells as […] March 23, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 22 Mar 2017 Swedish Oncology Biotech Teams up with World Leading Cancer Center The Swedish biotech Aprea Therapeutics has entered a new collaboration with the Memorial Sloan Kettering Cancer Center to study the effects of its lead APR-246. Based in Stockholm, Aprea therapeutics is focusing on the development of its only drug candidate, APR-246. The molecule targets the key tumor supressor p53 to restore its function. Now, in collaboration […] March 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email